导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.40% | 3595/4773 |
| 近一周 | -2.27% | 3663/5465 |
| 近一月 | -1.69% | 1235/5421 |
| 近一季 | 0.61% | 882/5231 |
| 近半年 | -6.06% | 3145/4920 |
| 近一年 | -10.71% | 3457/4394 |
| 近两年 | 36.74% | 2041/2954 |
| 近三年 | 33.31% | 957/2253 |
| 成立以来 | 17.58% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.38% 3824/4961 |
-9.16% 3944/5312 |
- - |
- - |
| 2025 | 27.82% 1533/4813 |
15.80% 157/3635 |
3.88% 928/4076 |
11.98% 3109/4524 |
-5.11% 3512/4813 |
| 2024 | 23.26% 342/3463 |
-1.43% 1225/2808 |
10.28% 41/3014 |
16.59% 1408/3129 |
-2.74% 2172/3463 |
| 2023 | -12.46% 1479/2656 |
0.25% 1746/2280 |
-0.69% 405/2385 |
-8.06% 1657/2515 |
-4.36% 981/2655 |
| 2022 | -5.00% 116/2207 |
-7.84% 254/1919 |
6.06% 775/2016 |
-14.08% 1019/2113 |
13.12% 109/2208 |
| 2021 | -11.77% 1115/1822 |
5.02% 122/1255 |
0.61% 1090/1330 |
-11.65% 1275/1466 |
-5.49% 1512/1822 |
| 2020 | -6.79% 978/1250 |
-14.25% 954/1028 |
3.87% 926/1067 |
-6.48% 1122/1164 |
11.90% 510/1184 |
| 2019 | 12.03% 718/1092 |
9.27% 722/754 |
1.48% 124/804 |
-5.42% 795/850 |
6.82% 540/918 |
| 2018 | -7.35% 63/834 |
- - |
- - |
- - |
-6.41% 45/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方恒指ETF联接(LOF)A VS. 长安沪深300非周期A(740101) |